Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ancrod - Nordmark Arzneimittel

Drug Profile

Ancrod - Nordmark Arzneimittel

Alternative Names: NM-V; Viprinex

Latest Information Update: 14 Sep 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Abbott Laboratories
  • Developer Abbott Laboratories; Neurobiological Technologies; Nordmark Arzneimittel
  • Class Antithrombotics; Serine endopeptidases; Venoms
  • Mechanism of Action Fibrinogen inhibitors; Plasminogen activator stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Heparin-induced thrombocytopenia and thrombosis syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Sensorineural hearing loss
  • Market Withdrawal Heparin-induced thrombocytopenia and thrombosis syndrome; Peripheral vascular disorders; Thromboembolism
  • Discontinued Stroke

Most Recent Events

  • 14 Sep 2020 No development reported - Phase-I/II for Sensorineural hearing loss in Germany, Czech Republic (SC)
  • 30 Oct 2018 Nordmark Arzneimittel completes a phase I/II trial in Sensorineural hearing loss in Czech Republic, Germany (SC) (IV) (NCT01621256)
  • 02 Jan 2013 Abbott separates its pharmaceuticals business to new company called AbbVie
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top